Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic…

By P. Mulvenna, M. Nankivell, R. Barton, C. Faivre-Finn, Paula Wilson, Elaine McColl, B. Moore, I. Brisbane, D. Ardron, T. Holt and 9 more. The Lancet, 2016

2,304 citations recorded by the source corpus.

Summary Background Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis of this patient group is poor. We aimed to establish whether WBRT could be omitted without a significant effect on survival or quality of life. Methods The Quality of Life after Treatment for Brain Metastases (QUARTZ) study is a non-inferiority, phase 3 randomised trial done at 69 UK and three Australian centres. NSCLC patients with brain metastases unsuitable for surgical resection or stereotactic radiotherapy were randomly assigned (1:1) to optimal supportive care (OSC) including dexamethasone plus WBRT (20 Gy in five daily fractions) or OSC alone (including dexamethasone). The dose of dexamethasone was determined by the patients' symptoms and titrated downwards if symptoms improved. Allocation to treatment group was done by a phone call from the hospital to the Medical Research Council Clinical Trials Unit at University College London using a minimisation programme with a random element and stratification by centre, Karnofsky Performance Status (KPS), gender, status of brain metastases, and the status of primary lung cancer. The primary outcome measure was quality-adjusted life-years (QALYs). QALYs were generated from overall survival and patients' weekly completion of the EQ-5D questionnaire. Treatment with OSC alone was considered non-inferior if it was no more than 7 QALY days worse than treatment with WBRT plus OSC, which required 534 patients (80% power, 5% [one-sided] significance level). Analysis was done by intention to treat for all randomly assigned patients. The trial is registered with ISRCTN, number ISRCTN3826061. Findings Between March 2, 2007, and Aug 29, 2014, 538 patients were recruited from 69 UK and three Australian centres, and were randomly assigned to receive either OSC plus WBRT (269) or OSC alone (269). Baseline characteristics were balanced between groups, and the median age of participants was 66 years (range 38–85). Significantly more episodes of drowsiness, hair loss, nausea, and dry or itchy scalp were reported while patients were receiving WBRT, although there was no evidence of a difference in the rate of serious adverse events between the two groups. There was no evidence of a difference in overall survival (hazard ratio 1·06, 95% CI 0·90–1·26), overall quality of life, or dexamethasone use between the two groups. The difference between the mean QALYs was 4·7 days (46·4 QALY days for the OSC plus WBRT group vs 41·7 QALY days for the OSC group), with two-sided 90% CI of −12·7 to 3·3. Interpretation Although the primary outcome measure result includes the prespecified non-inferiority margin, the combination of the small difference in QALYs and the absence of a difference in survival and quality of life between the two groups suggests that WBRT provides little additional clinically significant benefit for this patient group. Funding Cancer Research UK, Medical Research Council Clinical Trials Unit at University College London, and the National Health and Medical Research Council in Australia.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2adf29e3609d91db2a51a84fd9107824cbaf6631

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Joyce
2. D. Quail
3. K. Kerr
4. M. Hellmann
5. C. Hudis
6. R. Weinberg

Citations in the corpus

• The microenvironmental landscape of brain tumors (2017, positive): “Consistently, administering tumor lysate vaccines in combination with an FcOX40L fusion protein (a T cell co-stimulatory molecule) results in a 50% cure rate via enhanced tumoricidal lymphocytes, and long-term immunologic memory against glioma cells (Murphy et al., 2012).”
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “With this in mind, extended adjuvant therapy should be discussed with all patients, except the ones with a very low risk, although the optimal duration and regimen of adjuvant ET is currently unknown [I, C] [115].”
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. (2014, methodology): “This includes two randomized trials— one published and the other presented at the 2013 ASCO Annual Meeting— on extended durations of tamoxifen treatment.(9,10) The 2010 guideline update referred to a historical standard of 5-year duration of tamoxifen monotherapy, because earlier studies of extended”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “Premenopausal other Tamoxifen 5 – 10 years or OFS plus tamoxifen or OFS plus exemestane See criteria in papers [3,4,116]”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, positive): “Hippocampus avoidance WBRT has been shown to be probably safe [269], but is still undergoing trial evaluation and is not currently recommended for routine care [III, C].”
• Prospective Validation of a 21-Gene Expression Assay in Breast Cancer (2015, neutral): “Premenopausal 480/1623 (30) 2477/6873 (36)”